ECTRIMS 2023 | Impact of DMTs on pregnancy and postpartum in MS patients

Wei Yeh, MD, Monash University, Melbourne, Australia, emphasizes the significance of family planning in the care of patients with multiple sclerosis (MS), given its prevalence among young adults, particularly women. The study sought to determine the interaction between disease-modifying therapies (DMTs) and MS activity during pregnancy and the early postpartum period, specifically focusing on ocrelizumab. The study encompassed almost 2000 pregnancies, including 73 pregnancies in women treated with ocrelizumab pre-conception. Results highlighted that patients on ocrelizumab exhibited low relapse rates during pregnancy and postpartum, comparing favorably against other DMTs. A contrasting effect on relapse rates was observed between different natalizumab administration timelines: earlier discontinuation and later restarting of natalizumab was associated with higher relapse rates during and after pregnancy, compared to continuing natalizumab into the third trimester and restarting within one month of delivery. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.